Skip to main content

Advertisement

SpringerLink
Log in

Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Bacteraemia of unknown origin is prevalent and has a high mortality rate. However, there are no recent reports focusing on this issue. From 2005 to 2011, all episodes of community onset bacteraemia of unknown origin (CO-BSI), diagnosed at a 700-bed university hospital were prospectively included. Risk factors for Enterobactericeae resistant to third-generation cephalosporins (3GCR-E), Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus spp, and predictors of mortality were assessed by logistic regression. Out of 4,598 consecutive episodes of CO-BSI, 745 (16.2 %) were of unknown origin. Risk factors for S. aureus were male gender (OR 2.26; 1.33–3.83), diabetes mellitus (OR 1.71; 1.01–2.91) and intravenous drug addiction (OR 17.24; 1.47–202); for P. aeruginosa were male gender (OR 2.19; 1.10–4.37) and health-care associated origin (OR 9.13; 3.23–25.83); for 3GCR-E was recent antibiotic exposure (OR 2.53; 1.47–4.35), while for enterococci, it was recent hospital admission (OR 3.02; 1.64–5.55). Seven and 30-day mortality were 8.1 % and 13.4 %, respectively. Age over 65 years (OR 2.13; 1.28–3.55), an ultimately or rapidly fatal underlying disease (OR 4.15; 2.23–7.60), bone marrow transplantation (OR 4.07; 1.24–13.31), absence of fever (OR 4.45; 2.25–8.81), shock on presentation (OR 10.48; 6.05–18.15) and isolation of S. aureus (OR 2.01; 1.00–4.04) were independently associated with mortality. In patients with bacteraemia of unknown origin, a limited number of clinical characteristics may be useful to predict its aetiology and to choose the appropriate empirical treatment. Although no modifiable prognostic factors have been found, management optimization of S. aureus should be considered a priority in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bearman GML, Wenzel RP (2005) Bacteremias: a leading cause of death. Arch Med Res 36:646–659. doi:10.1016/j.arcmed.2005.02.005

    Article  PubMed  Google Scholar 

  2. Hoyert DL, Ph D, Xu J (2012) National vital statistics reports deaths: Preliminary data for 2011. National VitalStatistics Reports, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 61(6)1–52

  3. Lark RL, Saint S, Chenoweth C, Zemencuk JK, Lipsky BA, Plorde JJ (2001) Four-year prospective evaluation of community-acquired bacteremia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 41:15–22

    Article  PubMed  CAS  Google Scholar 

  4. Pedersen G, Schønheyder HC, Sørensen HT (2003) Source of infection and other factors associated with case fatality in community-acquired bacteremia—a Danish population-based cohort study from 1992 to 1997. Clin Microbiol Infect 9:793–802

    Article  PubMed  CAS  Google Scholar 

  5. Retamar P, López-Prieto MD, Nátera C, de Cueto M, Nuño E, Herrero M et al (2013) Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis 13:344. doi:10.1186/1471-2334-13-344

    Article  PubMed  PubMed Central  Google Scholar 

  6. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD (1998) The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244:379–386

    Article  PubMed  CAS  Google Scholar 

  7. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155

    Article  PubMed  CAS  Google Scholar 

  8. Ortega M, Almela M, Martinez JA, Marco F, Soriano A, López J et al (2007) Epidemiology and outcome of primary community-acquired bacteremia in adult patients. Eur J Clin Microbiol Infect Dis 26:453–457. doi:10.1007/s10096-007-0304-6

    Article  PubMed  CAS  Google Scholar 

  9. Vallés J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E et al (2008) Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 56:27–34. doi:10.1016/j.jinf.2007.10.001

    Article  PubMed  Google Scholar 

  10. Rodríguez-Baño J, López-Prieto MD, Portillo MM, Retamar P, Natera C, Nuño E et al (2010) Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect 16:1408–1413. doi:10.1111/j.1469-0691.2009.03089.x

    Article  PubMed  Google Scholar 

  11. Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M (1992) Bacteremia and fungemia of unknown origin in adults. Clin Infect Dis 14:436–443

    Article  PubMed  CAS  Google Scholar 

  12. Larsen IK, Pedersen G, Schønheyder HC (2011) Bacteraemia with an unknown focus: is the focus de facto absent or merely unreported? A one-year hospital-based cohort study. APMIS 119:275–279. doi:10.1111/j.1600-0463.2011.02727.x

    Article  PubMed  Google Scholar 

  13. Kollef MH, Zilberberg MD, Shorr AF, Vo L, Schein J, Micek ST et al (2011) Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect 62:130–135. doi:10.1016/j.jinf.2010.12.009

    Article  PubMed  Google Scholar 

  14. Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB (2012) The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 12:85. doi:10.1186/1471-2334-12-85

    Article  PubMed  PubMed Central  Google Scholar 

  15. Beceiro A, Tomás M, Bou G (2013) Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 26:185–230. doi:10.1128/CMR.00059-12

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123:1615–1624

    Article  PubMed  Google Scholar 

  17. Wester AL, Dunlop O, Melby KK, Dahle UR, Wyller TB (2013) Age-related differences in symptoms, diagnosis and prognosis of bacteremia. BMC Infect Dis 13:346. doi:10.1186/1471-2334-13-346

    Article  PubMed  PubMed Central  Google Scholar 

  18. Pien BC, Sundaram P, Raoof N, Costa SF, Mirrett S, Woods CW et al (2010) The clinical and prognostic importance of positive blood cultures in adults. Am J Med 123:819–828. doi:10.1016/j.amjmed.2010.03.021

    Article  PubMed  Google Scholar 

  19. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE et al (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237–1248. doi:10.1378/chest.09-0087

    PubMed  Google Scholar 

  20. Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV et al (2012) Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 56:472–478. doi:10.1128/AAC.00462-11

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M et al (2012) Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect 18:862–869. doi:10.1111/j.1469-0691.2011.03679.x

    Article  PubMed  CAS  Google Scholar 

  22. Laupland KB, Ross T, Gregson DB (2008) Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis 198:336–343. doi:10.1086/589717

    Article  PubMed  Google Scholar 

  23. Schechner V, Nobre V, Kaye KS, Leshno M, Giladi M, Rohner P et al (2009) Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis 48:580–586. doi:10.1086/596709

    Article  PubMed  Google Scholar 

  24. Kang C-I, Chung DR, Peck KR, Song J-H (2012) Clinical predictors of Pseudomonas aeruginosa or Acinetobacter baumannii bacteremia in patients admitted to the ED. Am J Emerg Med 30:1169–1175. doi:10.1016/j.ajem.2011.08.021

    Article  PubMed  Google Scholar 

  25. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C et al (2010) Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50:40–48. doi:10.1086/649537

    Article  PubMed  Google Scholar 

  26. Cardoso T, Ribeiro O, Aragão IC, Costa-Pereira A, Sarmento AE (2012) Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis 12:375. doi:10.1186/1471-2334-12-375

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gavaldà J, López P, Martín T, Gomis X, Ramírez JL, Azuaje C et al (2002) Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis. Antimicrob Agents Chemother 46:378–384. doi:10.1128/AAC.46.2.000

    Article  PubMed  PubMed Central  Google Scholar 

  28. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z et al (2011) Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 17:1581–1586. doi:10.1111/j.1469-0691.2010.03425.x

    Article  PubMed  CAS  Google Scholar 

  29. Flamm RK, Sader HS, Farrell DJ, Jones RN (2012) Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother 56:2933–2940. doi:10.1128/AAC.00330-12

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. File TM, Wilcox MH, Stein GE (2012) Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 55(3):S173–S180. doi:10.1093/cid/cis559

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in part by the “Fundación Máximo Soriano Jiménez” (Barcelona, Spain).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Hospital Clínic-IDIBAPS—Barcelona Centre for International Health Research (CRESIB), Barcelona University, Villarroel 170, 08036, Barcelona, Spain

    C. Hernandez, N. Cobos-Trigueros, C. Feher, L. Morata, C. De La Calle, A. Soriano, J. Mensa, A. Del Rio & J. A. Martinez

  2. Department of Clinical Microbiology, Hospital Clínic-IDIBAPS—Barcelona Centre for International Health Research (CRESIB), Barcelona University, Barcelona, Spain

    F. Marco & M. Almela

Authors
  1. C. Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Cobos-Trigueros
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Feher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Morata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. De La Calle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Almela
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Mensa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Del Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. A. Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Hernandez.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hernandez, C., Cobos-Trigueros, N., Feher, C. et al. Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome. Eur J Clin Microbiol Infect Dis 33, 1973–1980 (2014). https://doi.org/10.1007/s10096-014-2146-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-014-2146-3

Keywords

Search

Navigation